Mindmed reports topline data from phase 1 trial of mm-110 in development for the treatment of opioid withdrawal

- positive safety and tolerability results support the advancement of mm-110 and guide the phase 2a dose design in individuals undergoing supervised opioid withdrawal - - phase 2a trial remains on track to initiate in q2 2022 - new york , may 19, 2022 /prnewswire/ -- mind medicine (mindmed) inc (nasdaq: mnmd), (neo: mmed), (the "company" or "mindmed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced topline results from the phase 1 placebo-controlled trial designed to assess the safety, tolerability, pharmacokinetics and neurocognitive effects of mm-110 in 108 healthy volunteers. the results showed favorable safety and tolerability, support the advancement of mm-110, and have guided the phase 2a dose, schedule, and design in individuals undergoing supervised opioid withdrawal.
MNMD Ratings Summary
MNMD Quant Ranking